Clinical Trial Update: A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating RDEA806 in hyperuricemic subjects with symptomatic gout has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout
• Hyperuricemia

Drugs mentioned

• RDEA806 (RDEA806)

Snippet

Sponsor: Ardea Biosciences, Inc. | Conditions: Hyperuricemia | Phase 2 | Status: COMPLETED